EGFR and neoplasm: Thus, attention should be payed to implementation of a sensitive indel calling in bioinformatic pipelines to avoid missing of clinically relevant alterations such as for example activating indels in the exon 19 of the EGFR gene or truncating indels in tumor suppressor genes.